SEC Comment Letter for Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) (LRMR) — Apr 30, 2020
Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)
Date: April 30, 2020 · CIK: 0001374690 · Accession: 0000000000-20-003699
AI Filing Summary & Sentiment
File numbers found in text: 001-36510
Letter
United States securities and exchange commission logo April 30, 2020 Patty Allen Chief Financial Officer Zafgen, Inc. 3 Center Plaza, Suite 610 Boston, Massachusetts 02108 Re:Zafgen, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 6, 2020 File No. 001-36510 Dear Ms. Allen: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Goodman, Esq.
Show Raw Text
United States securities and exchange commission logo
April 30, 2020
Patty Allen
Chief Financial Officer
Zafgen, Inc.
3 Center Plaza, Suite 610
Boston, Massachusetts 02108
Re:Zafgen, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed March 6, 2020
File No. 001-36510
Dear Ms. Allen:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew Goodman, Esq.